Abstract
Purpose We performed a first-in-human clinical trial. The aim of this study was to determine safety and feasibility of PET imaging with 18F-PARPi in patients with head and neck cancer.
Patients and Methods Eleven patients (age 49 to 86 years) with newly diagnosed or recurrent oral and oropharyngeal cancer were injected intravenously with 18F-PARPi (331 ± 42 MBq) and dynamic PET/CT imaging was performed between 0 min and 25 min post-injection. Static PET/CT scans were obtained at 30 min, 60 min and 120 min p.i. Blood samples for tracer concentration and metabolite analysis were collected. Blood pressure, ECG, oxygen levels, clinical chemistry and CBC were obtained before and after administration of 18F-PARPi.
Results 18F-PARPi was well-tolerated by all patients without any safety concerns. Of the 11 patients included in the analysis, 18F-PARPi had focal uptake in all primary lesions (n = 10, SUVmax = 2.8 ± 1.2) and all 18F-FDG positive lymph nodes (n = 34). 18F-PARPi uptake was seen in 18F-FDG negative lymph nodes of three patients (n = 6). Focal uptake of tracer in primary and metastatic lesions was corroborated by CT alone or in combination with 18F-FDG. Contrast for 18F-PARPi and 18F-FDG was comparable (SUVmax(lesion)/SUVmax(genioglossus) = 3.3 and 3.0, respectively; p = 0.23), and SUVmax values for 18F-PARPi were less variable compared to 18F-FDG (1.3 versus 6.0, p = 0.001).
Conclusions Imaging of head and neck cancer with 18F-PARPi is feasible and safe. 18F-PARPi detects primary and metastatic lesions, and retention in tumors is longer than in healthy tissues.
Competing Interest Statement
S.P., C.B., J.S.L. and T.R. are shareholders of Summit Biomedical Imaging, LLC. S.P. and T.R. are co-inventors on filed U.S. patent (WO2016164771) that covers methods of use for PARPi-FL. T.R. is co-inventor on U.S. patents (WO2012074840 and WO2016033293), covering the compositions of matter for PARPi-FL and 18F-PARPi, respectively. T.R. is a paid consultant for and has received grant support from Theragnostics, Inc., which has licensed 18F-PARPi. This arrangement has been reviewed and approved by Memorial Sloan Kettering Cancer Center in accordance with its conflict of interest policies.
Clinical Trial
NCT03631017
Funding Statement
This work was supported in part by National Institutes of Health grants R01 CA204441, R35 CA232130 and P30 CA008748, the Tow Foundation, the MSK Center for Molecular Imaging * Nanotechnology, the MSK Imaging and Radiation Sciences Program and the MSK Molecularly Targeted Intraoperative Imaging Fund.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Footnotes
Translational Relevance. Preclinically, labeled PARP1-targeted olaparib derivatives have been used to visualize several malignancies with high contrast, including head and neck cancer. These results suggest that PARP1-targeted imaging agents could potentially be used as a quantitative whole body imaging test for primary and metastatic lesions, improving diagnostic sensitivity and specificity compared to the standard of care. This first-in-human study of 18F-PARP1 in patients with head and neck cancer established that imaging with the olaparib-based PARP1 imaging agent 18F-PARPi is feasible and safe, and that contrast ratios in the head and neck region are comparable to 18F-FDG. Retention in tumors and metastatic nodes is longer than in physiological tissues, including the salivary glands. The lymph node detection rate for 18F-PARPi is higher than for 18F-FDG, and a subset of 18F-PARPi positive and 18F-FDG negative lymph nodes resolved after chemoradiation. Further study of 18F-PARPi in head and neck cancer is being pursued.
Funding. This work was supported in part by National Institutes of Health grants R01 CA204441, R35 CA232130 and P30 CA008748, the Tow Foundation, the MSK Center for Molecular Imaging & Nanotechnology, the MSK Imaging and Radiation Sciences Program and the MSK Molecularly Targeted Intraoperative Imaging Fund.
Conflict of Interest Disclosure Statement. S.P., C.B., J.S.L. and T.R. are shareholders of Summit Biomedical Imaging, LLC. S.P. and T.R. are co-inventors on filed U.S. patent (WO2016164771) that covers methods of use for PARPi-FL. T.R. is co-inventor on U.S. patents (WO2012074840 and WO2016033293), covering the compositions of matter for PARPi-FL and 18F-PARPi, respectively. T.R. is a paid consultant for and has received grant support from Theragnostics, Inc., which has licensed 18F-PARPi. This arrangement has been reviewed and approved by Memorial Sloan Kettering Cancer Center in accordance with its conflict of interest policies.
Data Availability
Supplementary data is available online or from the corresponding authors.